Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Ho

Showing results (11-20 of 143) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Glypican-3: a new target for cancer immunotherapyMitchell Ho, Heungnam Kim
Antibody Therapeutics|October 9, 2018
DNA damaging agent-based antibody-drug conjugates for cancer therapyYing Fu, Mitchell Ho
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Mammalian cell display for antibody engineeringMitchell Ho, Ira Pastan
Methods in Molecular Biology (Clifton, N.J.)|June 26, 2009
Display and selection of scFv antibodies on HEK-293T cellsMitchell Ho, Ira Pastan
European Journal of Cancer (Oxford, England : 1990)|October 20, 2007
Mesothelin targeted cancer immunotherapyRaffit Hassan, Mitchell Ho
Antibody Therapeutics|October 20, 2025
CAR NK cell therapy for solid tumors: potential and challengesYanlin Yu, Mitchell Ho
Cancer Reports|May 8, 2012
The role of glypican-3 in regulating Wnt in hepatocellular carcinomasWei Gao, Mitchell Ho
Current Protocols in Protein Science|August 10, 2018
Isolation of Antibodies to Heparan Sulfate on Glypicans by Phage DisplayHeungnam Kim, Mitchell Ho
Molecular Cancer Therapeutics|June 26, 2021
T-Cell Receptor Mimic Antibodies for Cancer ImmunotherapyZhijian Duan, Mitchell Ho
Methods in Molecular Biology (Clifton, N.J.)|February 14, 2022
Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for NeuroblastomaNan Li, Mitchell Ho
Pageof 15

Showing results (11-20 of 143) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Glypican-3: a new target for cancer immunotherapyMitchell Ho, Heungnam Kim
Antibody Therapeutics|October 9, 2018
DNA damaging agent-based antibody-drug conjugates for cancer therapyYing Fu, Mitchell Ho
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Mammalian cell display for antibody engineeringMitchell Ho, Ira Pastan
Methods in Molecular Biology (Clifton, N.J.)|June 26, 2009
Display and selection of scFv antibodies on HEK-293T cellsMitchell Ho, Ira Pastan
European Journal of Cancer (Oxford, England : 1990)|October 20, 2007
Mesothelin targeted cancer immunotherapyRaffit Hassan, Mitchell Ho
Antibody Therapeutics|October 20, 2025
CAR NK cell therapy for solid tumors: potential and challengesYanlin Yu, Mitchell Ho
Cancer Reports|May 8, 2012
The role of glypican-3 in regulating Wnt in hepatocellular carcinomasWei Gao, Mitchell Ho
Current Protocols in Protein Science|August 10, 2018
Isolation of Antibodies to Heparan Sulfate on Glypicans by Phage DisplayHeungnam Kim, Mitchell Ho
Molecular Cancer Therapeutics|June 26, 2021
T-Cell Receptor Mimic Antibodies for Cancer ImmunotherapyZhijian Duan, Mitchell Ho
Methods in Molecular Biology (Clifton, N.J.)|February 14, 2022
Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for NeuroblastomaNan Li, Mitchell Ho
Pageof 15